Neurocrine Q1: INGREZZA sales $506M (+23% YoY); GAAP EPS $0.42, non-GAAP EPS $1.20

NEUROCRINE BIOSCIENCES INC

2024-Q1 EPS reported $0.42 revenue$515,300,000

INGREZZA net product sales $506M in Q1 2024 vs $411M in Q1 2023, up 23% year-over-year.
GAAP net income $43.4M ($0.42 diluted EPS) vs net loss $76.6M ($0.79 loss) in Q1 2023.
Non-GAAP net income $124.8M ($1.20 diluted EPS) vs net loss $49.5M ($0.51 loss) a year ago.
Total revenues $515.3M (+23% YoY); cash & equivalents $1.91B at quarter end.
FDA approved INGREZZA SPRINKLE; NDAs submitted for crinecerfont in congenital adrenal hyperplasia.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEUROCRINE BIOSCIENCES INC reported the first quarter ended March 31, 2024 results: revenue $515.3 million, net income $43.4 million, EPS $0.42. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $515.3 million
Net income: $43.4 million
EPS: $0.42
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-24-000116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.